Background: To reduce the incidence of drug resistance and to maintain viral suppression, patients chronically infected with HBV might require combination therapy using two or more drugs with different resistance profiles. We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro. Methods: Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV). We evaluated the uptake and phosphorylation of CLV in the presence of TBV, using HepAD38 cells and primary hepatocytes to determine the effect of TBV on the phosphorylation of CLV and vice versa. Phosphorylation of TBV and CLV to their corresponding monophosphate by deoxycytidine kinase, thymidine kinase-1 and thymidine kinase-2, and the phosphorylation of TBV monophosphate and CLV monophosphate by thymidylate kinase was evaluated and compared. Results: When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response. The results of in vitro metabolism and enzyme studies suggest that the antagonism observed with the CLV/TBV combination involves competition for uptake and phosphorylation. Conclusions: The results of our studies demonstrate that combination treatments can provide enhanced antiviral activity and, when used in conjunction with appropriate metabolic investigations, provide a rational basis for the design and development of combination regimens for treating chronic HBV infection.
HBV infection constitutes a major worldwide health threat. In addition to the morbidity associated with acute clinical infection, chronic liver disease, cirrhosis and primary hepatocellular carcinoma are recognized sequelae [1, 2] . It is estimated that there are 350 million chronic carriers worldwide [2] . Although a vaccine is available, chemotherapy remains the only treatment option for controlling chronic HBV infection. To date, interferon-α, lamivudine (3TC), adefovir (ADV), entecavir (ETV), telbivudine (TBV) and, more recently, tenofovir (TFV) are therapeutic options for the treatment of chronic HBV infection in the US. Clevudine (CLV) is a nucleoside analogue of the unnatural l-configuration that has potent anti-HBV activity in vitro and in vivo [3] .
Long-term monotherapy with nucleoside/nucleotide analogues has led to the emergence of mutations in the HBV polymerase that confer drug resistance. Clinically, the appearance of mutations conferring drug resistance has been associated with virological breakthrough, clinical deterioration and deterioration of the liver. Experience with HIV has shown that drug combinations, including dual-nucleoside therapy, can significantly improve chronic viral disease management, enabling significant viral load suppression, thus preventing or delaying the emergence of drug-resistant mutations and thereby prolonging patient benefit by slowing disease progression. In a study using primary duck hepatocytes, Seigneres et al. [4] demonstrated that the combinations of CLV and emtricitabine (FTC), and CLV and amdoxovir
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gave a synergistic antiviral response. Furthermore, in a follow-up in vivo study in ducks, the combination of CLV and FTC gave the greatest inhibition compared with the combination of CLV and amdoxovir, as well as the individual drugs alone given as monotherapy [4] . From the perspective of different mutation patterns, as well as the perspective of complementary sites of action against the HBV polymerase, a combination of l-and d-nucleoside/nucleotide analogues would be of interest. CLV shows a sustained antiviral effect in both the woodchuck HBV animal model [5] and in short-term clinical trials in HBV chronic carriers [3, [6] [7] [8] . In this report, we describe in vitro studies designed to assess the activity of CLV against HBV replication in human cell culture in combination with 3TC, ADV, ETV, TBV and TFV. Structures for these nucleoside/nucleotide analogues are shown in Figure 1 .
Methods

Materials
CLV, 3TC, ADV and TFV were provided by Hetero Drugs (Hyderabad, India), and ETV and TBV were synthesized by American Custom Chemicals (San Diego, CA, USA) and CMS Chemicals (London, UK), respectively.
3 H]-labelled CLV and TBV were purchased from Moravek Biochemicals (Brea, CA, USA). CLV monophosphate (MP) was synthesized by TriLink Biotechnologies (San Diego, CA, USA) and TBV-MP was synthesized by NuBlocks (Vista, CA, USA). The HepAD38 cell line, which expresses wild-type HBV (ayw subtype) under the control of an inducible tetracycline promoter was provided by BK. Primary human hepatocytes in six-well collagen-coated plates were purchased from CellzDirect (Pittsboro, NC, USA) or Cambrex (Walkersville, MD, USA). Human deoxycytidine kinase (dCK), thymidine kinase-1 (TK-1) and thymidine kinase-2 (TK-2) were cloned, expressed and purified as described previously [9, 10] . Human thymidylate kinase (TMPK) was amplified from human skeletal muscle total RNA (Clontech, Mountain View, CA, USA) by nested-PCR. Skeletal muscle RNA was reverse transcribed using Superscript III First Strand Synthesis kit (Invitrogen Technologies, Carlsbad, CA, USA) with random hexamers and TMPK was amplified by nested-PCR primers complementary to the untranslated region (5′-GCG TCT CCA GTG GGC AGC CTT GGG TCA-3′ and 5′-CGG CGC GGT GGA CAG TCA TGG CGG-3′) in the presence of 1 mM MgCl 2 . The coding sequence of TMPK was amplified using primers containing NdeI and BamHI sites (5′-GGA ATT CCA TAT GGC GGC CCG GCG CGG-3′ and 5′-CGC GGA TCC TCA CTT CCA TAG CTC-3′) for insertion into pET 28a+ (Novagen, Stamford, CT, USA) in frame with the N-terminal His tag and thrombin cleavage site. The TMPK expression construct was then transformed . The cells were grown in LuriaBertani medium with kanamycin (30 µg/ml) at 37°C and when the optical density at 600 nm reached 0.8, the expression of TMPK was induced by adding 0.5 mM isopropyl-b-d-thio-galactoside and the cells were further grown for 3 h at 30°C. The His-tagged protein was purified by metal affinity column chromatography using HisPur Cobalt Resin (Pierce, Rockford, IL, USA).
The protein was eluted with a linear gradient of 10-250 mM imidazole in a buffer containing 50 mM Tris/HCl (pH 8.0) and 300 mM NaCl. The eluted protein was concentrated using an Amicon Ultra-4 centrifugal filter unit with an Ultracel-10 membrane from Millipore (Billerica, MA, USA) and dialyzed against a storage buffer containing 50 mM Tris/HCl (pH 7.4), 50 mM NaCl, 1 mM DTT and 50% glycerol.
HBV AD38 assays
HepAD38 cells (used under a licence from TET Systems GmbH, Heidelberg, Germany) were maintained in Dulbecco's modified Eagle's/F12 medium (DMEM/ F12; Invitrogen Technologies) supplemented with 10% fetal bovine serum, 50 µg/ml penicillin, 50 µg/ ml streptomycin, 100 µg/ml kanamycin, 0.3 µg/ml tetracycline at 37°C and 5% carbon dioxide. The 50% effective concentration (EC 50 ) values for the individual compounds were determined as described previously [11, 12] . Briefly, on day 0, HepAD38 cells were seeded into 96-well plates at 5×10 4 cells/well in 200 µl of medium and incubated at 37ºC in a 5% carbon dioxide atmosphere. On day 2, medium was removed and the cells were washed once with phosphate-buffered saline (PBS). Duplicate cultures were treated with six threefold serial dilutions of each drug. On day 7, HepAD38 cell supernatant was collected and stored for analysis. Viral DNA was extracted from extracellular HBV using DNeasy ® 96 Tissue kit (Qiagen, Valencia, CA, USA) in a 96-well format. DNA was eluted in a total volume of 100 µl and 5 µl was used for real-time PCR analysis in a final reaction volume of 25 µl. For realtime PCR, HBV primers (forward 5′-GGA CCC CTG CTC GTG TTA CA-3′ and reverse 5′-GAG AGA AGT CCA CCA CGA GTC TAG A-3′) were used at 22.5 pmol/reaction and a probe (5′-FAM TGT TGA CAA GAA TCC TCA CAA TAC CAC AGA-3′) was used at 5 pmol/reaction (IDT, Coralville, IA, USA) and Taqman ® Universal PCR Master Mix was added at 2× concentration (Applied Biosystems, Inc., Foster City, CA, USA). The antiviral activity of each drug was analysed by real-time PCR using an ABI 7500 Real Time PCR System (Applied Biosystems, Inc.).
For combination studies, compounds were mixed at molar ratios designed to give approximately equipotent antiviral effects and diluted in medium without tetracycline. Three different molar ratios were used for each combination to allow for variability in the estimates of relative potency. Six threefold serial dilutions were then made of the starting drug mixtures, maintaining the same ratio for all dilutions such that the concentration range for the combinations covered ratios corresponding to the in vitro EC 90 , EC 75 , EC 50 and EC 25 values for the individual compounds and for the combinations. The corresponding monotherapies were assayed in parallel. Duplicate cultures were treated with six threefold serial dilutions of each combination or monotherapy. On day 7, HepAD38 cell supernatants were collected and treated as described above.
Data analyses
The combination effects were determined by the median effect methods described by Chou and Talalay [13] using the CalcuSyn™ programme (Biosoft, Inc., Cambridge, UK). Evaluations of synergy, additivity or antagonism at different levels of virus inhibition were performed. For the fraction of virus affected combination index (Fa-CI) plot analysis, a combination index (CI)>1.0 indicates antagonism and a CI<1.0 indicates synergism. The data were also evaluated using the isobologram method. With this method, if the data point falls on the diagonal, an additive effect is indicated, if it falls on the lower left of the diagonal, synergism is indicated and if the point falls on the upper right of the diagonal, antagonism is indicated.
Phosphorylation studies
HepAD38 cells and primary human hepatocytes were incubated with either 1 µM [ 3 H]-CLV (30,000 DPM/ pmol) in the presence and absence of increasing concentrations of TBV or 1 µM [ 3 H]-TBV (12,000 DPM/ pmol) in the presence and absence of increasing concentrations of CLV for 24 h. At the end of the incubation, extracellular medium was removed and the cell layer was washed with cold PBS. After trypsinization, cells were counted and centrifuged at 1,200 rpm for 5 min. The cell pellets were suspended in 1 ml of cold 60% methanol and then incubated overnight at -20°C. The samples were centrifuged at 14,000 rpm for 5 min and the supernatants were dried using a SpeedVac Concentrator (Thermo Electron Corporation, Waltham, MA, USA) and then stored at -20°C until they were analysed by HPLC. Residues were redissolved in 100 µl of water and 50 µl aliquots were injected into HPLC. The phosphorylated derivatives of CLV and TBV were separated by ion-exchange HPLC with a Whatman 10 µm SAX column (Whatman, Maidstone, UK) using a Series 200 HPLC system (PerkinElmer, Wellesley, MA, USA). The mobile phase consisted of buffer A (0.02 M KH 2 PO 4 , pH 3.5) and buffer B (1 M KH 2 PO 4 , pH 3.5). Elution was performed using a linear gradient of buffer B from 0 to 100% for 90 min. Radioactivity was analysed using a 610TR Radiometric Flow Scintillation Analyzer (PerkinElmer). The respective phosphorylated forms of CLV and TBV were identified on the basis of the retention time of synthesized standards of the phosphorylated forms of CLV and TBV.
Kinase assays
Phosphorylation of nucleoside and nucleoside MP by human dCK, TK-1, TK-2 and TMPK was studied spectrophotometrically as described previously [9] . The reaction was coupled with pyruvate kinase and lactate dehydrogenase, and oxidation of NADH was followed at 340 nm using a Lambda 35 UV/VIS Spectrometer (PerkinElmer, Boston, MA, USA). The reaction temperature was 37°C. A 1 ml reaction contained 64 mM TrisHCl (pH 7.5), 3.8 mM EDTA, 180 mM KCl, 12.8 mM MgCl 2 , 24 mM (NH 4 ) 2 SO 4 , 1 mM ATP, 0.5 mM phosphoenolpyruvate, 0.1 mM NADH, 5 IU/ml pyruvate kinase, 13.8 IU/ml lactate dehydrogenase, and varying concentrations of nucleoside or nucleoside MP substrate and kinase. The final enzyme concentration for dCK, TK-1, TK-2 and TMPK reactions was 319 nM, 369 nM, 334 nM and 217 nM, respectively. The reaction rate at different concentrations of the nucleoside substrate was determined and steady-state parameters were calculated using the GraFit programme version 5 (Erithacus Software, Horley, Surrey, UK).
RNA isolation and real-time PCR
Total RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA (1 µg) was used for complementary DNA (cDNA) synthesis using High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative real-time PCR was performed using TaqMan ® Universal PCR Master Mix (Applied Biosystems) on ABI 7500 Real Time PCR System. The TaqMan ® Gene Expression Assays used for dCK, TK-1 and TK-2 were Hs00176127_m1, Hs00177406_m1 and Hs00177950_m1, respectively. The 18s rRNA was used as an endogenous control. All experiments were performed in triplicates. Relative messenger RNA levels were calculated according to ∆∆CT method and expressed as fold difference relative to the amount extracted from Huh7 cells.
Results
Activity of individual drugs
To determine EC 50 values for the individual compounds, HepAD38 cells were incubated with the test compounds for 7 days after the removal of tetracycline to allow HBV expression and virus replication as described in Methods. Extracellular HBV DNA was isolated and quantified by real-time PCR and the viral DNA reduction was measured to evaluate the antiviral activity of each compound. The EC 50 values for each drug are summarized in Table 1 . The comparative antiviral activity of the individual compounds tested was ETV>ADV=3TC>CLV=TFV>TBV. Relative ratios of the individual drugs used in the subsequent combination studies were based on the EC 50 values of each of the individual drugs.
Two-drug combination assays
The anti-HBV effect of combining CLV with 3TC, ADV, ETV, TFV and TBV was evaluated using the HepAD38 cell assay system. Each of the combination studies was performed using three different molar ratios designed to give equipotent antiviral effects and to allow for variability in the estimates of relative potency. Using the CalcuSyn™ programme, the data from these studies was evaluated by means of Fa-Cl and isobologram plots ( Figure 2D ) and ETV ( Figure 2E) ; however, when CLV was combined with TBV, an antagonistic effect was observed ( Figure 2F ). As a control experiment for the assay a combination of CLV plus CLV was evaluated. As expected, an additive effect was seen with the CLV plus CLV combination (Figure 2A ).
Effect of nucleoside/nucleotide analogues on CLV phosphorylation
Combination studies involving the two thymidine analogue inhibitors of HIV, stavudine (d4T) and zidovudine (AZT), demonstrated that the two drugs were moderately antagonistic when used together in cell culture [14] . Hoggard et al. [15] and Ho and Hitchcock [16] demonstrated that AZT significantly reduced the intracellular level of the phosphorylated forms of d4T. Hoggard et al. [15] demonstrated that a small reduction in AZT phosphorylation was observed with d4T. Because intracellular phosphorylation of nucleoside analogues defines their activity, we evaluated the phosphorylation of CLV in the presence of TBV to determine if TBV caused a reduction in the phosphorylation of CLV and vice versa. These experiments were performed in both HepAD38 cells and primary human hepatocytes. Higher levels of both CLV and TBV metabolites were found in primary human hepatocytes compared with HepAD38 cells (Figure 3) . In both HepAD38 cells and primary human hepatocytes, in the absence of competing nucleoside, the total intracellular concentration of nucleoside metabolites was much higher with CLV than with TBV, indicating that CLV is transported into the cell more efficiently than TBV. Incubating HepAD38 cells with 1 µM [ 3 H]-CLV in the presence of increasing concentrations of unlabelled TBV resulted in reduced levels of CLV-MP, CLV-diphosphate (DP) and CLV-triphosphate (TP) in a dose-dependent manner ( Figure 3A) . Similarly, when [ 3 H]-TBV was incubated with unlabelled CLV, a dosedependent reduction in the level of TBV-MP, TBV-DP and TBV-TP was observed ( Figure 3B ). However, CLV was a more potent inhibitor of the phosphorylation of TBV than TBV was of CLV phosphorylation, especially at the DP and TP levels ( Figure 3A and 3B ). An identical study was performed with primary human hepatocytes. In these experiments, TBV demonstrated a similar degree of inhibition of CLV phosphorylation but CLV showed much stronger inhibition of TBV phosphorylation in primary hepatocytes than it did in the HepAD38 cells ( Figure 3C and 3D) . Interestingly, the levels of TBV-DP and TBV-TP were inhibited by >90% in the presence of 1 µM CLV, whereas even in the presence of 50 µM TBV, the reduction in CLV-TP level was only 42% (Figure 3C and 3D) . Furthermore, when the total intracellular radioactivity (nucleosides and nucleotides) was plotted against increasing concentrations of exogenous unlabelled competing nucleoside (Figure 4 ), a decrease in total radioactivity was observed as the competing nucleoside concentration increased for both HepAD38 cells ( Figure 4A ) and primary human hepatocytes ( Figure 4B ).
Enzyme kinetic assays
Nucleoside analogues must be phosphorylated to their active TP form to inhibit HBV polymerase. Phosphorylation of TBV and CLV to their corresponding MP by dCK, TK-1 and TK-2 was evaluated and compared. As shown in Table 2 , dCK phosphorylated CLV approximately 10-fold more efficiently than TBV, but both of these compounds were phosphorylated significantly less efficiently than the natural substrate 2′-deoxycytidine. TK-1 phosphorylated TBV and CLV 165-and 39-fold less efficiently than thymidine, respectively. TK-2, however, phosphorylated TBV at the same efficiency as the natural thymidine, whereas CLV was phosphorylated only slightly more efficiently than thymidine by TK-2 ( Table 2) . The phosphorylation of TBV-MP and CLV-MP was studied using cytosolic TMPK. TBV-MP and CLV-MP were both phosphorylated efficiently to their corresponding DPs (Table 3) .
Gene expression of dCK, TK-1 and TK-2
Gene expression levels of dCK, TK-1 and TK-2 in Huh7, HepAD38 and primary human hepatocytes from two donors were evaluated in order to identify the enzyme(s) that contribute to the phosphorylation of TBV and CLV. As shown in Table 4 , dCK gene expression levels in primary hepatocytes was lower than that in Huh7 or HepAD38 cells. It is known that TK-1 is not expressed in non-proliferating cells [17, 18] . Our results agree with this observation as the amount of TK-1 gene expression in primary hepatocytes was extremely low with approximately 0.3-0.7% of the level in Huh7 cells and 6-13% of the level in HepAD38 cells (Table 4 ). In addition, TK-1 protein was not detected in the cell extract of primary hepatocytes by western blot analysis (TT, data not shown). The gene expression level of TK-2 was similar in Huh7, HepAD38 and primary hepatocytes.
Discussion
Progress in the development of effective therapeutic regimens to treat chronic HBV infection has been slow. Long-term antiviral therapy is required for most patients. The major drawback of prolonged therapy is the emergence of resistant HBV variants that arise through spontaneous mutations because of the error rate and lack of proofreading capability of the viral polymerase. In this respect, HBV shares certain similarities with HIV; therefore, there are valuable lessons to be learned from HIV clinical experience that should be considered for the management of chronic HBV infection. The use of combination therapy for the treatment of HIV infection has proven effective in improving the magnitude and duration of antiviral efficacy and delaying the development of resistance. Similarly, management of chronic HBV patients will also require combination therapy using drugs with different resistance profiles to maintain viral suppression and delay or to prevent the emergence of resistant virus. Although HBV drugs are mainly nucleoside/nucleotide analogues that target the viral polymerase, their specific mode of action might involve anti-priming, anti-reverse transcriptase activity, anti-DNA-dependent DNA polymerase activity and/or a combination of these activities [19, 20] . Furthermore, not all nucleoside/nucleotide drugs share the same resistance mutations. Early studies with combinations of nucleoside analogues demonstrated that some combinations of nucleoside analogues show enhanced or synergistic activity [4, 21, 22] . In primary duck hepatocytes infected with duck HBV, the combination of ADV, 3TC and penciclovir demonstrated synergistic activity [21, 23] . A short-term study in acutely infected ducklings evaluating the efficacy of CLV in combination with amdoxovir or FTC showed that 7 days of treatment with the dual combinations gave greater inhibition than either of the drugs given as monotherapy [4] . These studies suggest that combining CLV with other nucleoside/nucleotide inhibitors might provide enhanced efficacy in vitro. In this study, using the HepAD38 cell line that expresses wild-type HBV and a quantitative real-time PCR assay, we evaluated the anti-HBV activity of CLV in combination with 3TC, ETV, TBV, ADV or TFV. The anti-HBV activity of each drug was evaluated first as monotherapy. The relative anti-HBV activity in our assay was ETV>ADV=3TC>CLV=TFV>TBV.
Our in vitro combination studies demonstrated that when CLV was combined with 3TC, ETV, ADV or TFV, this resulted in a synergistic anti-HBV effect. However, when CLV was combined with TBV, antagonistic interactions were observed in our assay, implying that these compounds are incompatible. Although the combination of CLV and 3TC results in a synergistic anti-HBV effect, 3TC selects for the 204 and 180/204 mutations to which CLV is cross-resistant [24] [25] [26] . Given the shared cross-resistance profile between CLV and 3TC, the likelihood that this combination would be useful is low. By contrast, CLV does not share crossresistance patterns with ETV, ADV or TFV; therefore, combinations of CLV with ETV, ADV or TFV demonstrate in vitro compatibility.
In vitro combination studies in HIV-infected cells demonstrated that an antagonistic antiviral effect occurred when two thymidine analogues, AZT and d4T, were tested in combination. Ho and Hitchcock [16] performed experiments to measure the effect of AZT on the phosphorylation of d4T and vice versa. They demonstrated that when both compounds were added to cells simultaneously at the same concentration, AZT inhibited the phosphorylation of d4T but d4T did not inhibit the phosphorylation of AZT. Similarly, Hoggard et al. [15] reported that AZT significantly inhibited the phosphorylation of d4T in peripheral blood mononuclear cells. However, in contrast to the studies of Ho and Hitchcock [16] , Hoggard et al. [15] showed that d4T caused a slight inhibition of AZT phosphorylation depending upon the ratio of d4T to AZT. We therefore performed metabolism studies with CLV and TBV to determine if the antagonistic effect observed with the CLV/TBV combination in the AD38 assay followed a similar mechanism of interference. When HepAD38 cells and primary human hepatocytes were incubated with either [ [27] demonstrated that CLV can be transported into cells by the equilibrative-sensitive nucleoside transport system with high nitrobenzylthioinosine affinity and equilibrative-insensitive nucleoside transport system with low affinity to nitrobenzylthioinosine. The results presented in Figure 4 , showing that the level of total intracellular radioactive species (nucleoside and nucleotides) were reduced by the competing nucleoside, suggest that the uptake of CLV and TBV might involve the same transporter(s). This effect was most pronounced in primary human hepatocytes, particularly when CLV was the competitor, suggesting that CLV has a greater affinity than TBV for the transporter(s) involved in the uptake of these compounds.
Because TK-1 gene expression was very low compared with Huh7 cells and the protein expression was not detected in primary hepatocytes, then cytosolic dCK and/or mitochondrial TK-2 are the enzymes most probably responsible for phosphorylating CLV in hepatocytes. Liu et al. [27] also have demonstrated that dCK, TK-1 and TK-2 are capable of phosphorylating CLV, which was confirmed in our studies. They suggested that the major enzyme phosphorylating CLV is cytosolic dCK and CLV might be transported into mitochondria and be phosphorylated by TK-2 in the liver. If CLV is phosphorylated by dCK in the cytoplasm, the second phosphorylation step presumably would be catalysed by TMPK. If instead CLV is transported into mitochondria and phosphorylated by TK-2 then the phosphorylated form of CLV will probably be exported from mitochondria. It was proposed that export of phosphorylated thymidine occurs at the DP level [28] ; therefore, if CLV is phosphorylated to CLV-MP by TK-2 in mitochondria, the second phosphorylation might be catalysed by an, as yet unidentified, mitochondrial kinase. Xu et al. [29] recently identified a mitochondrial uridine monophosphate-cytidine monophosphate kinase 2. Although this enzyme did not phosphorylate dTMP to dTDP, it shares high sequence homology with TMPK [29, 30] . It is possible that CLV-MP might be a substrate for uridine monophosphate-cytidine monophosphate kinase 2. We have previously shown that the major metabolite of CLV found in human primary hepatocytes is CLV-MP and the rate-limiting step for the CLV activation is phosphorylation of CLV-MP to CLV-DP [31] . This indicates that the first phosphorylation step must be processed more efficiently than the second step. According to our enzyme kinetic data, the efficiency (k cat /K m ) for TMPK was higher than that for cytosolic dCK and TK-1, whereas mitochondrial TK-2 demonstrated very high efficiency. Therefore, our data suggest that CLV activation in primary hepatocytes, at least in part, involves the mitochondrial pathway. Prospects for managing chronic HBV infection have improved significantly in the past decade; however, in the majority of patients, viral replication rapidly returns to pretreatment levels following the withdrawal of therapy. In addition, drug-resistant variants have been identified in a significant number of drug-treated patients. Experience with HIV suggests that combination therapy with two or more drugs that have different resistance profiles might suppress or eliminate drug resistance. Basic research into the mechanism of action of drugs and their interaction should assist in the design and optimization of future combinations of drugs to treat chronic HBV infection. The in vitro studies reported here demonstrate that combination treatments can provide enhanced antiviral activity and, when used in conjunction with appropriate metabolic investigations, provide a rational basis for the design and development of combination regimens for more efficacious therapies for chronic HBV infection.
